Adebrelimab plus Apatinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy, plus Apatinib, a targeted therapy) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC) that is not suitable for surgery or has returned after treatment.
- You have already received at least one type of systemic therapy, such as targeted therapy with or without immunotherapy.
- You have not been treated with the specific drugs Adebrelimab or Apatinib before.
- Your liver function is still good (Child-Pugh class A) and you are able to do most daily activities (ECOG 0-1).
- You have at least one tumor that can be clearly measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial tests whether combining two drugs, camrelizumab (an immunotherapy) and apatinib (a targeted therapy), can prevent liver cancer from coming back in people who've had surgery or ablation to remove their tumor. It's for patients with a high risk of recurrence.
This study tests a combination of two drugs (apatinib and adebrelimab) with standard chemotherapy for people with bile duct cancer that cannot be removed surgically. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Hepatocellular Carcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.